About Yi-Bin Chen, MD

Yi-Bin Chen grew up in New Jersey.  He majored in molecular biophysics and biochemistry, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital, including an additional year as Chief Resident. This was followed by a fellowship in hematology/oncology at the Dana-Farber Partners combined program. In 2008, he joined the staff of the Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center, has served as Director of Clinical Research since 2012 and was named overall Program Director in 2016. His interests mainly revolve around improving the outcomes of patients undergoing autologous and allogeneic stem cell transplantation. He has led original clinical trials involving all aspects of BMT, including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and two children.   

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Hematology/Oncology Bone Marrow Transplant
55 Fruit St
Boston, MA 02114-2696
617-726-5765
617-724-1124
Fax: 617-643-5843

Medical Education

  • MD, Harvard Medical School
  • Residency, Massachusetts General Hospital
  • Fellowship, Dana Farber Cancer Institute

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Chen is the Director for the BMT program at MGH. His research interests mainly revolve around improving the outcomes for patients undergoing autologous and allogeneic stem cell transplantation. He serves as institution and overall principal investigator for many clinical trials. MGH is an active participant in several national collaborative group trials, specifically from Alliance and the BMT CTN. In addition, Dr. Chen currently lead the following investigative efforts:

  • Use of brentuximab vedotin to target CD30 in the treatment of acute graft-vs-host disease (GVHD)
  • Inhibition of the FLT3 mutation after allogeneic transplant for patients with FLT3-ITD mutated AML
  • Use of third-party fecal microbiota transplantation to restore microbiome diversity in recipients of BMT
  • Use of vedolizumab for the prevention and treatment of acute intestinal GVHD
  • Combined bone marrow and kidney transplantation using partially matched family donors

Dr. Chen invites you to contact him directly to inquire about the latest clinical investigations available at MGH.

Publications

  • Select Publications:

    • Chen YB, et al. Upregulation of a4b7 integrin on peripheral blood memory T-cells predicts for intestinal graft-versus-host disease (GVHD) following allogeneic stem cell transplantation. BBMT. 2009;15:1066-76.
    • Chen YB, et al. Expression of CD30 in Patients with Acute Graft-vs.-Host Disease. Blood. 2012; 120(3):691-6.
    • Chen YB, Cutler CS. Biomarkers for acute GVHD: can we predict the unpredictable? BMT. 2013;48(6):755-60.
    • Brunner A, ... and Chen YB. Outcomes of Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. BBMT. 2013; 19(9):1374-80.
    • Chen YB, et al. “Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML.” BBMT. 2014, 20(12):2042-8.
    • El-Jawahri A, ...and Chen YB. “Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.” BBMT. 2016; 22(5):910-918.
    • Brunner AM, ... and Chen YB. “Haematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukaemia in CR1.” British Journal of Haematology. 2016; 175(3):496-504.
    • DeFilipp Z and Chen YB. “Strategies and Challenges for Maintenance Therapies Following Allogeneic Hematopoietic Cell Transplantation.” Biol Blood Marrow Transplant. 2016; 22(12):2134-2140.